Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Gains from Sales and Divestitures: 2015-2021

Historic Gains from Sales and Divestitures for ImmunityBio (IBRX) over the last 5 years, with Jun 2021 value amounting to $336,084.

  • ImmunityBio's Gains from Sales and Divestitures fell 39.88% to $336,084 in Q2 2021 from the same period last year, while for Jun 2021 it was $336,084, marking a year-over-year decrease of 39.88%. This contributed to the annual value of $648,336 for FY2020, which is 64.11% up from last year.
  • Per ImmunityBio's latest filing, its Gains from Sales and Divestitures stood at $336,084 for Q2 2021, which was up 42.57% from $235,725 recorded in Q1 2021.
  • Over the past 5 years, ImmunityBio's Gains from Sales and Divestitures peaked at $648,336 during Q4 2020, and registered a low of $6,625 during Q1 2017.
  • Over the past 3 years, ImmunityBio's median Gains from Sales and Divestitures value was $291,842 (recorded in 2019), while the average stood at $333,482.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first crashed by 93.04% in 2017, then spiked by 959.62% in 2018.
  • ImmunityBio's Gains from Sales and Divestitures (Quarterly) stood at $244,209 in 2017, then fell by 29.43% to $172,330 in 2018, then spiked by 129.24% to $395,051 in 2019, then surged by 64.11% to $648,336 in 2020, then slumped by 39.88% to $336,084 in 2021.
  • Its last three reported values are $336,084 in Q2 2021, $235,725 for Q1 2021, and $648,336 during Q4 2020.